Selected advances in therapy of urologic cancer--luteinizing hormone releasing hormone (LHRH) and biologic response modifier (BUR).
Javadpour
N
N
University of Maryland, School of Medicine, Division of Urology, Baltimore, 21201.
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D002064:Buserelin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D007376:Interleukin-2; D011994:Recombinant Proteins; D017273:Goserelin; D002064:Buserelin